Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

World News

King Charles cancels engagements after experiencing temporary side effects of cancer treatment

by admin March 28, 2025
March 28, 2025
King Charles cancels engagements after experiencing temporary side effects of cancer treatment

Britain’s King Charles “required a short period of observation in hospital” on Thursday after experiencing “temporary side effects” from a scheduled cancer treatment in the morning, Buckingham Palace has said.

“His Majesty has now returned to Clarence House and as a precautionary measure, acting on medical advice, tomorrow’s diary program will also be rescheduled,” the palace said in a statement.

“His Majesty would like to send his apologies to all those who may be inconvenienced or disappointed as a result,” it added.

The King was set to receive credentials from the ambassadors of three countries on Thursday, and was scheduled to undertake four public engagements in Birmingham, central England, on Friday.

Charles’ cancer diagnosis was first announced in February last year, after he underwent a “corrective procedure” for a benign enlarged prostate the month before.

He briefly stepped away from public-facing duties while he received treatment for the undisclosed form of cancer, returning to them a few months later in April 2024. In his first official engagement since his diagnosis, Charles visited a cancer treatment center, where he leaned on his own personal experience when talking to medical teams as well as while connecting with patients and their families.

Thousands of people sent the King messages of support when he was first diagnosed, which he said “reduced me to tears,” according to a statement released by Buckingham Palace at the time. “Such kind thoughts are the greatest comfort and encouragement,” Charles said.

This is a developing story and will be updated.

This post appeared first on cnn.com

previous post
India among top suppliers of illicit fentanyl precursors, US intelligence report says
next post
FCC is investigating Disney and ABC for DEI initiatives

Related Posts

Firefighting pilot killed in helicopter crash as South...

March 26, 2025

A fiery collision in the North Sea has...

March 11, 2025

Romania’s outgoing president quits to pre-empt impeachment bid...

February 11, 2025

Europe’s busiest airport is set to get bigger,...

January 30, 2025

First major piece of Bayesian superyacht recovered from...

May 20, 2025

Toddler held in US after parents’ deportation has...

May 15, 2025

Italian prime minister says she is being investigated...

January 29, 2025

A day of confusion and chaos as Russia...

May 16, 2025

Ukraine ramps up calls for ‘pressure’ on Russia...

May 17, 2025

Clashes erupt in western India as Hindu groups...

March 19, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 5

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved